Biotech Sector Faces Major Downturn, Shows Signs of Recovery
Since early 2021, the iShares Biotechnology ETF (IBB) has experienced a 33% downturn, contrasting with the S&P 500 Index’s 60% gain in the same period. This bear market primarily affected clinical-stage biotech firms, with many losing over 50% of their value. Factors contributing to this decline include rising interest rates, reduced post-COVID investment interest, and stringent regulations from the Biden Administration on mergers and acquisitions.
Recent market movements indicate a potential recovery for biotechnology. The IBB displayed relative strength amidst a broader market decline on a recent trading day, gaining nearly 1%. The ETF is nearing a breakout from a five-year price base, suggesting an upward trend could be on the horizon.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
